Xoma, Novartis deal

Xoma granted Novartis exclusive, worldwide rights to develop and commercialize its antibody program targeting transforming growth factor (TGF) beta (TGFB). The deal includes preclinical candidate XOMA 089, a mAb targeting TGFB1 and TGFB2. Novartis declined to disclose the indications the company will pursue for XOMA 089. In July, Xoma said it hoped to out-license the compound for development in immuno-oncology and fibrosis. ...